Bio-Technology General Euflexxa 1% Sodium Hyaluronate

Nazione: Singapore

Lingua: inglese

Fonte: HSA (Health Sciences Authority)

Commercializzato da:

FERRING PHARMACEUTICALS PRIVATE LIMITED

Classe:

Class D medical device

Prodotto da:

Bio-Technology General (Israel) Ltd.

Area terapeutica:

Orthopaedics

Indicazioni terapeutiche:

EUFLEXXA is indicated for the treatment of pain caused by osteoarthritis of the knee, hip, temporomandibular, carpometacarpal, shoulder and ankle joints. EUFLEXXA aids in lubrication of the joint, allows for greater mobility and flexibility of the treated joint, and reduces pain in the affected joint.

Dettagli prodotto:

Device System Info:[Sterile Medical Device], EUFLEXXA is packed in a single-use, aseptically-filled disposable sterile 2.25 ml syringe (nominal volume) containing either 1 ml or 2 ml of 1% microbial fermentation-derived NaHA in phosphate-buffered saline; Models: Euflexxa 1% Sodium Hyaluronate - 3 x 2ml, Euflexxa 1% Sodium Hyaluronate - 1 x 2ml

Data dell'autorizzazione:

2017-04-28